STOCK TITAN
  1. Home
  2. News
  3. ABBV

AbbVie to Host Third-Quarter 2023 Earnings Conference Call

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
AbbVie to announce Q3 2023 financial results on October 27, 2023
Positive
  • None.
Negative
  • None.

NORTH CHICAGO, Ill., Oct. 4, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its third-quarter 2023 financial results on Friday, October 27, 2023, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT. It will be accessible through AbbVie's Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.

 

Cision View original content:https://www.prnewswire.com/news-releases/abbvie-to-host-third-quarter-2023-earnings-conference-call-301942331.html

SOURCE AbbVie

Stock ABBV logo
ABBVIE INC.

NYSE:ABBV

ABBV Rankings

#30 Ranked by Market Cap
#2312 Ranked by Stock Gains
#912 Ranked by Dividends

ABBV Latest News

Apr 26, 2024
AbbVie Reports First-Quarter 2024 Financial Results
Apr 25, 2024
New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study
Apr 23, 2024
Allergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands
Apr 18, 2024
Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
Apr 12, 2024
AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine

ABBV Stock Data

287.98B
1.76B
0.11%
71.92%
0.74%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
NORTH CHICAGO

About ABBV

AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.